PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows

Phase 2 Not yet recruiting 27 enrolled Haitao Niu, MD

Non-randomizedSequentialOpen-labelTreatment

Summary

a Phase II, single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.

Timeline

Start: 2026-02-27
Primary completion: 2026-07-27
Completion: 2026-09-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DGPR1008	Diagnostic / imaging agent	0.04 mg/kg	Intravenous

Indications

No indication recorded.